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Abstract: Stem cell and cell reprogramming technology represent a rapidly growing field in
regenerative medicine. A number of novel neural reprogramming methods have been established,
using pluripotent stem cells (PSCs) or direct reprogramming, to efficiently derive specific neuronal cell
types for therapeutic applications. Both in vitro and in vivo cellular reprogramming provide diverse
therapeutic pathways for modeling neurological diseases and injury repair. In particular, the retina
has emerged as a promising target for clinical application of regenerative medicine. Herein, we review
the potential of neuronal reprogramming to develop regenerative strategy, with a particular focus on
treating retinal degenerative diseases and discuss future directions and challenges in the field.
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1. Introduction
The vertebrate retina is a multi-layer tissue at the back of the eye that is responsible for visual
function. The transmission of the visual information starts with the conversion of photons energy
into membrane potential changes by the photoreceptors. Within the outer nuclear layer, the rod
photoreceptors are responsible for dim-light vision, while the cone photoreceptors are involved in
acuity and color vision [1]. Electrical signals are transmitted from the photoreceptors to the surrounding
bipolar cells which extract and convey visual signals to the retinal ganglion cells (RGCs), the output
neurons of the retina. The signal transductions along this vertical pathway—from photoreceptors to
bipolar cells to RGCs—are modulated by inhibitory interneurons at two different levels, horizontal
cells and amacrine cells in the outer and inner plexiform layer, respectively [2,3]. Ultimately, the visual
signals are transmitted by the RGCs that formed the optic nerve to the visual cortex. Given the
complexity of the retina, damage to any individual neuron class within the neural retina could lead to
disruption of the retinal function and vision loss.
Pathologies of the neural retina represent some of the most common causes of vision impairment
and blindness [4]. Two major retinal degenerative disorders are age-related: glaucoma, which is
caused by degeneration of the optic nerve; and age-related Macular Degeneration (AMD), which is
characterized by degeneration of retinal pigment epithelium (RPE) and photoreceptors. These two
retinal dystrophies combine to affect 250–280 million patients worldwide [5,6]. In addition, over 200
genes have been identified to cause degeneration of different retinal cells in a number of inherited
retinal disorders (IRD) [7]. For example, retinitis pigmentosa causes irreversible vision loss due
to the degeneration of photoreceptors, while Leber’s hereditary optic neuropathy is an inherited
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mitochondrial disorder that results in degeneration of RGCs. Dominant optic atrophy is another
common IRD inherited in an autosomal dominant pattern with high penetrance, which also leads to
visual defects by damaging RGCs and the optic nerve. Importantly, there is no cure for these blinding
diseases once the retinal cells are lost. Thus, regenerative medicine has provided an attractive approach
to repair the retina and restore vision in patients. Here, we will review the current advances in using
pluripotent stem cells (PSCs) and direct reprogramming approaches to generate neurons and discuss
the opportunities and challenges in their application in retinal regeneration.
2. Induced Pluripotent Stem Cells (iPSCs) as a Cell Source for Neuron Production
Current advances in cell reprogramming technology allow the conversion of one cell type into
another, providing an attractive strategy to generate retinal neurons to repair the retina. Generally,
the cell identity of a terminally differentiated cell is remarkably stable, with limited cellular potential
to transform into other cell types. However, recent studies showed that forced expression of
fate-determining factors can reprogram mature cells into different cell fates. In a landmark study,
it was demonstrated that a single transcription factor, MyoD, is sufficient to convert fibroblast cells
and various other cell types into skeletal muscle cells [8]. A subsequent study showed that ectopic
expression of the eyeless, Drosophila homolog of PAX6, can induce eye development on the legs of
Drosophila [9], demonstrating another remarkable example of cell-fate reprogramming by a single
transcription factor. In addition, the seminal studies from Shinya Yamanaka’s group described a way
to induce cellular pluripotency experimentally; they successfully reprogrammed adult fibroblasts
to a pluripotent state with a defined cocktail of transcription factors. The resulting cells, iPSCs, are
similar to embryonic stem cells (ESCs) and have the potential to differentiate into cell lineages of
all three germ layers [10,11]. Importantly, iPSCs represent a non-ethically disputed and virtually
infinite source of pluripotent cells [12], providing a new paradigm in regenerative medicine for a wide
range of diseases. Patient-specific iPSC can be expanded and differentiated into specific neurons that
are affected by the diseases, offering the unique opportunity to develop in vitro disease models for
retinal diseases, including work from our group and others [13–16]. iPSC-derived neurons carrying a
specific disease-related genetic background may serve as a robust platform for further investigation
of pathogenetic mechanisms and reveal disease-specific cellular phenotypes. These iPSC disease
models could be used for testing therapeutic interventions, such as candidate or novel drugs and
neuroprotective compounds [17].
3. Neuronal Differentiation of iPSCs Using Small Molecules and Growth Factors
The conventional strategy of neuronal differentiation involved first directing iPSCs differentiation
into neural progenitor cells (NPCs), followed by subsequent differentiation into functional neurons.
Generation of NPCs and differentiated neurons from iPSCs were largely based on various animal
studies of neurodevelopment, in which the major events of mammalian neural commitment are
identified. During neurodevelopment, a number of signaling pathways have been implicated in the
specification of cell fate within the neural tube. Sonic hedgehog (SHH) is secreted from the ventral
regions of the neural tube, whereas bone morphogenetic protein (BMP) and WNT proteins are secreted
from the dorsal regions [18–21]. These morphogen gradients specify different neuron types along the
dorsal-ventral axis, while neural fates commitment along the anterior-posterior axis is modulated by
various fibroblast growth factors (FGFs) and retinoic acid (RA) [22–24]. These signaling pathways
can be modulated by small molecules and/or growth factors to direct iPSCs into neuronal cell fates.
For instance, Lorenz Studer’s group first identified that inhibition of SMAD signaling with the noggin
protein and the small molecule inhibitor SB431542 increased the efficiency of neural differentiation
of both human ESCs and iPSCs into NPCs [25]. Building on this work, iPSC-derived NPCs can be
further differentiated into various neuronal subtypes, such as spinal cord motor neurons by treatment
with SHH, RA, and FGFs [26–28]. On the other hand, forebrain cortical neurons have been produced
by treating iPSCs with antagonists of the SHH pathway or combining dual-SMAD inhibition and
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WNT inhibition with anti-posteriorizing factors, such as Dickkopf-related protein 1 (DKK1) [29–31].
In addition, SHH, FGF8, and WNT1 can promote the specification of midbrain neurons, while activation
of BMP/SMAD was also reported to promote neurogenesis of midbrain dopaminergic neurons in
iPSCs [32–35].
PSCs also provide a valuable cellular source to generate in vitro retinal cells. The mammalian
eye is formed as an evagination from the diencephalon, the region of the neural tube that gives
rise to posterior forebrain structures. During development, inhibition of the WNT/BMP signaling
pathways are required for forebrain development [36,37], which is crucial for retinal formation as the
eye derives from the developing forebrain [38,39]. Furthermore, insulin-like growth factor-1 (IGF-1)
specifically promotes eye induction in the Xenopus embryos [40]. Based on this knowledge, Thomas
Reh’s group described an improved differentiation protocol by treating human ESCs-derived embryoid
bodies with DKK-1, noggin, and IGF-1 to generate retinal progenitor cells (RPCs) that could be further
differentiated into inner retinal neurons [41]. Building on this work, our group has further developed
a multi-stage differentiation protocol, together with magnetic-activated sorting (MACS), to enrich
RGCs [42]. Similar enrichment strategy for RGCs was also described by other groups [43,44].
Similarly, photoreceptors can be generated from adherent PSC-derived embryoid bodies by
inhibition of the WNT/BMP signaling pathways with noggin and DKK-1 [45,46]. The efficiency
for photoreceptor differentiation was further improved in a follow-up study using a three-step
photoreceptor differentiation protocol [47]. More recently, Zhu et al. reported the generation of
photoreceptors from clinical-grade iPSCs, which can functionally integrate into the mouse retina upon
transplantation [48]. Likewise, RPE cells can also be generated using human PSCs by removal of bFGF
from the culture medium [49–52]. Subsequent studies have improved the yields and kinetics of RPE
differentiation by addition of a range of small molecules and defined factors [53–57]. These approaches
give rise to induced RPE within 40–60 days, with classic hexagonal morphology, marker expression,
pigmentation, and phagocytic activity.
In addition to adherent differentiation culture, the recent development of organoids provided
an exciting 3D culture system for retinal differentiation. These retinal organoids broadly recapitulate
in vivo retinogenesis and retinal morphology, exhibiting appropriate apical-basal polarity and
development of major cell types into the laminated structure. In a landmark study, Eiraku et al. reported
that quick reaggregation of dissociated ESCs under differentiation conditions generates multilayer
retinal organoids. Surprisingly, these organoids demonstrated time-dependent self-patterning
of all major retinal cell types resembling that of the in vivo retina. Further Notch inhibition
at the later stage of differentiation promoted generation of photoreceptors [58,59]. Subsequent
improvements of differentiation protocols generated photoreceptors with rudimentary outer-segment
discs and light sensitivity, supporting the functional maturation of photoreceptors derived by this
organoid method [60–64]. Further maturation of the photoreceptors was achieved in a modified
2D/3D differentiation protocol, generating retinal organoids with photoreceptors bearing outer and
inner segments, connecting cilia, and presynaptic structures [65,66]. Notably, the differentiated
photoreceptors were able to incorporate into the mouse retina following transplantation, supporting the
potential application of PSC-derived retinal organoids for treating retinal degeneration. In summary,
the conventional strategy to mimic the neural developmental pathways, using small molecules
or recombinant growth factors, have achieved reasonable success in directing neural and retinal
differentiation of PSCs.
4. Neuronal Differentiation of iPSCs Using Transcription Factors
Transcription factor-based direct differentiation provides an alternative approach to efficiently
convert iPSCs into specific neuron types of interest. Compared to differentiation methods using small
molecules/growth factors, the use of transcription factors often promote differentiation with faster
kinetics, which in turn reduce the cost of cell production. Pang et al. demonstrated that hiPSCs can
be directed to become induced neurons (iNs) using a combination of transcription factors, ASCL1,
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POU3F2, and MYT1L [67]. Strikingly, forced expression of these three transcription factors reprograms
the hiPSCs into neurons in a short period of time, exhibiting bipolar neuron-like morphologies as early
as day 3 of differentiation. Neuronal markers, such as Class III β-tubulin and MAP2, were detected by
day 8, while action potentials were manifested as early as day 6. The rapid conversion of neuronal fate
demonstrated a faster path of transcription factor-based neural induction compared to conventional
differentiation using growth factors or signaling molecules. Subsequently, other groups have reported
different transcription factor cocktails that can promote differentiation towards specific neuronal
subtypes. ASCL1 has emerged as a potent neural reprogramming factor, with its combined expression
with other factors determining different neuronal cell fates. Co-expression of ASCL1, NR4A2, and
LMX1A promote neuronal reprogramming to dopaminergic neurons [68], whereas co-expression of
ASCL1 and DLX2 gave rise to GABAergic neurons [69]. On the other hand, sole expression of other
widely used pioneer factors, such as NEUROG2 or NEUROD1, has been shown to convert hiPSCs into
functional iNs with nearly 100% yield and purity in less than two weeks [70,71]. The use of synthetic
mRNA to deliver these transcription factors also provides a rapid, footprint-free method for neuronal
reprogramming of iPSC [72]. Further combination of LHX3 and ISL1 with NEUROG2 give rise to more
specific hiPSC-derived motor neurons, highlighting the high efficiency and robustness of transcription
factor-based direct differentiation [73].
Previous studies have also demonstrated the use of transcription factors to direct iPSC
differentiation into retinal neurons. Overexpression of Pax6 has been shown in mouse iPSCs to
push undifferentiated cells first into RPCs, followed by subsequent differentiation into a mixed
population of putative RGCs and photoreceptors [74]. A recent report also demonstrated the use of
DKK1, noggin, and Lefty A to first differentiate human iPSCs into RPCs, followed by overexpression
of ATOH7 to further induce differentiation into RGCs [75]. This study highlighted the potential of
combining small molecules and transcription factors to direct a step-wise retinal neuronal differentiation.
In summary, PSCs can be efficiently differentiated into various neuronal subtypes using growth factors,
small molecules, or transcription factors. Future studies in improving the robustness, efficiency, and
purity of the derived retinal neurons would greatly facilitate their use for tissue engineering and
cell therapy.
5. Direct Reprogramming to Generate Neurons Using Transcription Factors
Direct reprogramming offers an alternative route of lineage conversion that utilizes transcription
factor expression to allow a direct change of cellular identity and bypass most developmental stages.
Compared to iPSC, a major advantage of direct reprogramming is that it bypasses the procedure
of resetting somatic cells into a pluripotent state, thus reducing the time needed to derive neurons.
Previous studies by the Wernig lab showed that the combination of transcription factors POU3F2,
ASCL1, and MYT1L transforms both mouse and human fibroblasts into glutamatergic and GABAergic
neurons [67,76]. Further work showed that the proneural factor ASCL1 alone was able to guide the
conversion of human fibroblasts into a mix of glutamatergic and GABAergic neurons [77]. Interestingly,
ASCL1 promoted reprogramming of astrocytes to mainly GABAergic neurons [78]. This highlighted
that the effect of transcription factor to reprogram cell fate is partly dependent on the starting cell
type. A number of transcription factor combinations have been identified for neuronal reprogramming
in a range of somatic cell types. For example, astrocytes can also be reprogrammed into neurons
using NEUROG2, NEUROD1, or SOX2 individually [79–81]. Human retina-derived fibroblasts
have been induced into neuronal cells expressing mature neuronal markers, functional synapses, and
electrophysiology by the combined expression ofASCL1 and PAX6 [82]; human pericytes have also been
converted into neurons by expression of ASCL1 and SOX2 [83], and more specific cholinergic neurons
by expression of ASCL1, MYT1L, POU3F2, TLX3, and a microRNA miR-124 [84]. Other non-fibroblastic
cell sources, such as human T cells or cord blood cells, have also been successfully reprogrammed into
iNs using different combinations of factors [85,86]. Collectively, these studies supported the feasibility
of direct neuronal reprogramming from a range of different starting cell types.
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Generation of specific neuronal subtypes is important to improve modeling and advance cell
therapy for neurodegenerative diseases. As the master regulators for neuronal specification, ASCL1
and NEUROG2 are commonly used as the core factors and supplemented with other factors to
promote neuronal reprogramming to specific subtypes. Additional expression of LMX1A and FOXA2
with POU3F2, ASCL1, and MYT1L directs conversion of human fibroblasts toward dopaminergic
neurons [87], while a combination of fewer transcription factors—ASCL1, NR4A2, and LMX1A—also
generates functional dopaminergic neurons from both mouse and human fibroblasts [88]. On the other
hand, NEUROG2 can promote generation of cholinergic neurons from human fibroblasts with the help
of two small molecules, forskolin, and dorsomorphin [71,72]. Serotonergic neurons can be generated
from human fibroblasts by overexpression of NKX2-2, FEV, GATA2, and LMX1B in combination with
ASCL1 and NEUROG2 [89], or by an alternating set of transcription factors—ASCL1, FOXA2, FEV,
and LMX1B [90]. Interestingly, the conversion efficiency and yield of these serotonergic neurons were
significantly increased by p53 knockdown and hypoxic culturing condition [90], indicating a link
between p53 signaling, oxidation, and the reprogramming process.
A range of other transcription factor combinations have also been demonstrated to promote lineage
conversion into neurons with specialized function, for example, co-expression of POU4F1 with either
NEUROG1 orNEUROG2 direct human and mouse fibroblasts into neurons with properties of peripheral
sensory neurons, displaying expression of TrkA, TrkB, or TrkC receptors and electrophysiological
activity [91]. A combination of five factors, ASCL1, MYT1L, NEUROG1, ISL2, and KLF7, gives rise to
nociceptive neurons expressing specific receptors and channels, such as TRPA1, TRPM8, P2X3, and
SCN10A [92]. In addition, excitatory cortical neurons exhibiting electrophysiological properties and
key cortical neuronal markers were generated from human fibroblasts by overexpression of POU3F2,
MYT1L, and FEZF2. Notably, these iNs displayed a similar molecular signature to fetal cortical
neurons and were able to integrate and formed synaptic connections upon transplantation ex vivo into
organotypic cultures of adult human cerebral cortex [93].
In the retina field, direct reprogramming technology has been used in the generation of
photoreceptors, RPE, and RGCs. The transcription factors CRX, RAX, and NEUROD1 were used
to convert human iris cells into photoreceptor-like cells with expression of rhodopsin, S opsin, and
M/L opsins [94]. Subsequent studies from the same group showed that the same combination of
factors can direct reprogramming into photoreceptor-like cells from human dermal fibroblasts [95] or
peripheral blood mononuclear cells [96], providing more accessible cell sources compared to iris cells.
Interestingly, addition of OTX2 further improved this reprogramming process, resulting in higher
expression of photoreceptor-specific markers, such as S opsin, recoverin, S-arrestin, CNGB3, and
PDE6C [95]. Similarly, NEUROG1 can also reprogram human RPE cell lines into photoreceptor-like
neurons, with a range of marker expression including RBP3, recoverin, arrestin, transducin α-subunit,
CRX, and L/M opsin [97].
On the other hand, Müller glia represents a promising target for direct reprogramming into retinal
neurons, as they are the major glial cells in the retina that harbor evolutionary conserved stem and
progenitor potentials. Overexpression of ASCL1 in postnatal Müller glia promoted reprogramming
into a pool of iNs with properties of amacrine, bipolar cells, and photoreceptors [98]. Moreover,
overexpression of NEUROG2 can reprogram postnatal Müller glia into iNs with increased level of RGC
marker genes, such as POU4F1, SLC17A6, CALB2, SYN1, and PVALB [98]. Altogether, these studies
showed the potential of using transcription factors to drive direct reprogramming into various retinal
cell types.
6. Alternative Direct Reprogramming Approaches Using microRNA and Small Molecules
Besides transcription factors, the use of small molecules and/or microRNA represents an alternative
neuronal reprogramming approach. Application of small molecules can facilitate lineage conversion
by modulating developmental signaling pathways. For instance, a chemical cocktail of seven small
molecules (valproic acid, CHIR99021, RepSox, forskolin, SP600125, GO6983, and Y-27632) was shown
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to successfully convert human fibroblasts into neuronal cells [99]. Similarly, Wan et al. also reported
the use of five chemical cocktails (valproic acid, CHIR99021, DMH1, RepSox, forskolin, Y-27632, and
SP600125) to reprogram fibroblasts into neurons [100]. Other non-fibroblastic cell sources were also
tested for chemical reprogramming. Human fetal astrocytes were reprogrammed into glutamatergic
and GABAergic neurons by four small molecules, DAPT, CHIR99021, SB431542, and LDN193189 [101].
Apart from fetal astrocytes, treatment of valproic acid, CHIR99021, RepSox, forskolin, i-Bet151, and
ISX-9 also succeed in transforming human adult astrocytes into neurons. More recently, Mahato et al.
showed that fibroblasts can be chemically reprogrammed into rod photoreceptors using a set of
small molecules—valproic acid, CHIR99021, RepSox, forskolin, SHH, taurine, and RA. Notably,
transplantation of the reprogramed photoreceptors resulted in improvement in visual functions
in a mouse degenerative model [102], which highlighted the therapeutic potential of this direct
reprogramming strategy in treating blinding retinal diseases.
microRNAs are also reported to promote direct neuronal reprogramming. For instances, miR-9/9∗
and miR-124 are key neurogenic factors which are capable of reprogramming human fibroblasts
into neurons when combined with NEUROD1 [103,104]. Furthermore, miR-9/9∗ and miR-124 can
be supplemented with different transcription factors to generate specific neuronal subtypes, such as
striatal neurons when combined with BCL11B, DLX1, DLX2, and MYT1L [105,106], and spinal cord
motor neurons in combination with ISL1 and LHX3 [107]. microRNAs also play an important role
in directing glial-to-neuron reprogramming. For example, miR-128 can be used in combination with
NEUROD1, ASCL1, and LMX1A to reprogram astrocytes into dopaminergic neurons [108], whereas
miR-218 together with Ascl1 and Lmx1a can convert neuron-glia antigen 2 (NG2)-expressing glial cells
(NG2 glia) into parvalbumin-containing interneurons in mouse in vivo [109]. Collectively, these results
support the use of microRNAs to facilitate transcription factor-based neuronal reprogramming into
specific neuronal subtypes.
7. Opportunities for Stem Cell-based Therapies for Regenerative Medicine
iPSC and direct reprogramming provide two feasible strategies to derive human cells in vitro
for the development of cell therapy. A number of clinical trials for iPSC-derived products have
been initiated for the treatment of neurodegenerative diseases. In Japan, a Phase I/II clinical trial
led by Jun Takahashi is currently testing the efficacy of using iPSC-derived dopaminergic progenitor
cells to treat Parkinson’s disease [110,111]. In the eye, there are promising results for early trials
of RPE replacement therapy, with several ongoing phase I/II clinical trials for PSC-derived RPE
replacement [112–115]. More recent efforts in this field featured the use of human fetal-derived RPCs
to treat retinitis pigmentosa, including a Phase II trial with intravitreal delivery by JCyte [116] and a
PhaseI/II trial with subretinal delivery by ReNeuron [117,118]. The success of these trials would open
up possibilities for cell therapy as a treatment for neurodegenerative diseases. Similarly, the advent of
ESC/iPSCs provides a promising alternative source for photoreceptor transplantation. Recent studies
provided evidence for structural and functional integration of PSC-derived photoreceptor precursors
into the retinal circuits [48,65,119–125], supporting the clinically applicability of using PSC-derived
photoreceptors for cell therapy.
In comparison, the development of RGC replacement therapy is less advanced than those for RPE
and photoreceptors. Transplantation of primary RGCs can successfully integrate into the retinal circuitry,
supporting the feasibility of RGC replacement therapy [126,127]. In addition, preclinical animal studies
showed that transplantation of Müller glia-derived RGCs resulted in some degree of functional
recovery in RGC injury models [128,129]. However, limited studies have utilized PSC-derived RGCs
for transplantation. In an encouraging study, RPCs were extracted from hESC-derived retinal organoids
and transplanted into the vitreous cavity of a mouse model with RGC injury, where the transplanted
cells migrated and integrated into the ganglion cell layer in the host retina [130]. Further development
to upscale generation and purification of the stem cell-derived retinal cells would facilitate new
treatment for retinal regeneration. In particular, transplantation of retinal organoids provided an
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interesting strategy for cell therapy, as highlighted by recent studies to improve vision in a rodent
model with retinal degeneration [131].
8. Potential of Using In Vivo Reprogramming for Neuroregeneration
The emergence of in vivo reprogramming provided an exciting strategy to promote tissue
regeneration, by converting residential cells to replace cells that are lost in diseases or injury. Guo et al.
showed that overexpression of NeuroD1 can directly reprogram reactive glial cells in the cortex
into functional neurons in mouse models for Alzheimer’s diseases or stab-injury [132]. Interestingly,
astrocytes were mainly reprogrammed into glutamatergic neurons, while NG2 glia were reprogrammed
into a mix of glutamatergic and GABAergic neurons. Importantly, the reprogrammed neurons exhibited
synaptic responses, supporting the use of in vivo reprogramming to repair neurodegeneration in the
cortex [132]. A number of transcription factors have also been tested for neuronal reprogramming
in vivo. For instance, Ascl1, Pou3f2, and Myt1l can convert astrocytes into neuron-like cells in the
mouse brain [133], while Ascl1 alone is capable of reprogramming astrocytes into functional neurons
in young animals [134]. Neurog2 has been reported to reprogram astrocytes into neurons in the adult
rat brains when combined with FGF2 and EGF treatment, albeit at low efficiency [135]. The addition of
Bcl2 with Neurog2 also significantly increased the astrocyte-to-neuron reprogramming efficiency [136].
Besides astrocytes, NG2 glia can also be reprogrammed into neuronal cells upon ectopic expression of
Sox2 in a stab injury model [137]. These studies support the feasibility of neuronal regeneration using
an in vivo reprogramming approach.
The application of in vivo reprogramming to promote retinal regeneration is currently a topic
that attracts enormous interests. Early studies showed that inactivation of Nrl can promote direct
reprogramming of rod photoreceptors into cone-like cells, resulting in functional rescue of retinal
degeneration in a mouse model of retinitis pigmentosa [138,139]. A subsequent study further showed
that this strategy can improve visual responses in three different retinal degenerative models [140].
These studies pave the way for the development of in vivo reprogramming approaches to treat retinal
degenerative diseases.
Recently, a number of high-profile studies identified Müller glia as a potent target for in vivo
reprogramming into various retinal neurons. Tom Reh’s group showed that Ascl1 can successfully
reprogram endogenous Müller glia in mice into amacrine, bipolar cells, and photoreceptors in an
injury setting [141]. However, the regenerative response to injury was more pronounced in Müller glia
in young mice, suggesting a more restricted regenerative capacity of adult mice. Loss of neurogenic
capacity in mature Müller glia might be a result of reduced chromatin accessibility. Building on
this work, the same group showed that supplementation of a histone deacetylase inhibitor together
with Ascl1 can successfully reprogrammed endogenous Müller glia into functional retinal neurons in
adult mice [142]. These studies provided strong evidence to support the feasibility of using Müller
glia reprogramming to stimulate retinal regeneration. A subsequent study showed that endogenous
Müller glia can be reprogrammed into rod photoreceptors in healthy retina [143]. The authors
utilized a two-step strategy, which included β-catenin-induced Müller glia proliferation, followed
by reprogramming into rod photoreceptors using Otx2, Crx, and Nrl. Notably, the reprogrammed
rod photoreceptors in vivo can functionally integrate into the retinal and visual cortex circuits [143],
providing a critical step towards restoring vision by photoreceptor regeneration. More recently, Zhou
et al. exploited the RNA-targeting CRISPR system, CasRx, to knockdown Ptbp1 gene in Müller glia in
mouse, resulting in neuronal reprogramming to generate functional RGCs in vivo [144]. The authors
showed that the reprogrammed RGCs establish projections toward the dorsal lateral geniculate nucleus
and the superior colliculus, and can improve vision functions in a mouse model with retinal injury [144].
Interestingly, the group also showed that Ptbp1 knockdown in the striatum also promoted astrocyte
reprogramming into dopaminergic neurons and improved functional recovery in a mouse model of
Parkinson’s disease. These studies collectively support the feasibility of glia-to-neuron reprogramming
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to regenerate neurons in vivo, paving the path for future therapeutic applications for degenerative
diseases affecting the central nervous system (CNS) and the retina.
9. Gene Delivery System for Neuronal Reprogramming
The success of gene therapy depends greatly on appropriate gene delivery systems for introducing
therapeutic genetic materials into the target cells. Recent advances in viral vector engineering, delivery,
and safety have placed viral-based therapy at the forefront of the field of regenerative medicine.
Adenoviruses possess high transduction efficiency in a broad range of host cells and have been
commonly used as vectors in a large number of studies. Furthermore, adenoviruses do not integrate
into the host genome, leading to relatively transient but safe transgene expression. However, high
immune responses against adenoviruses limit their therapeutic efficacy for CNS gene therapy [145].
On the other hand, adeno-associated viruses (AAVs) have been applied extensively in clinical trials
for neurodegenerative diseases. Indeed, the first FDA-approved retinal gene therapy uses an AAV2
vector [146]. AAV2 has a well-established safety profile in humans and long-term expression in
neurons [147–149]. Additionally, the ability of AAV9 and AAVrh.10 to penetrate the blood–brain barrier
facilitates gene delivery and transduction in the CNS [150–152]. Interestingly, a recently engineered
AAV-PHP.B was reported to transduce the majority of astrocytes and neurons across multiple CNS
regions with an efficiency of at least 40-fold greater than that of the AAV9 capsids [153], demonstrating
the potential of engineered AAV vectors for therapeutic applications.
In contrast to AAVs and adenoviruses, lentiviruses are able to fully integrate DNA into the
host genome through reverse transcription, thus providing a more stable and long-lasting transgene
expression in vivo. As lentiviral vectors are able to package larger transgenes, they were utilised in
a clinical trial has utilized the usage of a lentiviral vector for patients with advanced Parkinson’s
disease [154]. Overall, viral vectors provide substantial flexibility and a range of therapeutic options
that make them potentially useful in a wide range of human diseases.
Apart from viral-based gene delivery systems, synthetic mRNAs have also been investigated for
therapeutic proteins expression and gene editing. Previous reports showed that transfection using lipid
or polymeric nanoparticles successfully deliver synthetic mRNAs into various cell types [155–157],
allowing transient production of encoded proteins with a lower risk of insertional mutagenesis.
Although clinical applications of synthetic mRNAs in the nervous system are limited thus far,
continued advances in mRNA manufacturing and intracellular delivery methods may ultimately lead
to the use of mRNA for the treatment of a wide range of neurodegenerative diseases.
10. Challenges and Future Direction for Neuronal Reprogramming
To facilitate clinical application of neuronal reprogramming and stem cells for cell therapy, we
need to overcome several major hurdles. Firstly, derivation of patient-specific iPSC for autologous cell
therapy is extremely costly, which would impact the availability of the treatment to many patients.
To address this, stem cell banks can be set up to provide human leukocyte antigen (HLA)-matched
iPSCs. In addition, advances have been made in the development of universal donor iPSC by knocking
down genes required for immune recognition, such as HLA class I and II proteins [158]. Secondly, cell
therapy often requires a high number of transplanted cells to achieve therapeutic effects, therefore
upscaling the manufacturing of iPSCs, as well as their differentiated derivatives, would be important.
The use of automated culture systems can improve cell production [159]. In addition, the development
of differentiation methods with improved efficiency, as well as the incorporation of cell purification or
enrichment strategies (i.e., flow cytometry), would help address this issue. Thirdly, the risk of tumor
formation using iPSC-derived cells for transplantation needs to be carefully managed. Rigorous quality
control of iPSC-derived cell products would be essential for the development of safe and effective stem
cell-based cell therapy.
On the other hand, in vivo reprogramming of endogenous glial cells represents an exciting
approach for neuronal regeneration. However, given that extensive levels of neuronal reprogramming
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are likely required to provide a therapeutic effect in diseases or injuries, there is a risk that in vivo
reprogramming may lead to depletion of the endogenous glial cells targeted for reprogramming.
Incorporation of strategy to stimulate glial cell proliferation during in vivo reprogramming could
be a key to this issue [143]. Further refinement of in vivo reprogramming methods, using
optimal reprogramming factor combination and gene delivery system, to improve on efficiency
and specificity would be crucial. The development of computational algorithms to predict transcription
factors for direct reprogramming provide an exciting tool to facilitate this research, as discussed
previously [160]. Secondly, for inherited neurodegenerative diseases it is important to note that
the regenerated cells stimulated by in vivo reprogramming would still harbor the disease-causing
mutations. Future studies that utilize combinatorial gene therapy to correct genetic mutations together
with in vivo reprogramming would be an interesting research direction in the field. Finally, it is
important that the regenerated cells stimulated by in vivo reprogramming are carefully characterized
for cell identity and functions to ensure the safety of this regenerative strategy.
11. Summary and Conclusion
Technological advances in cell reprogramming technology over the past few years have opened
up new opportunities for regenerative medicine targeting the central nervous system and the
retina. The feasibility of in vitro derivation, using iPSC or direct reprogramming, as well as in vivo
reprogramming to generate specific neurons, provide exciting regenerative strategies to repair the
nervous system in disease and injury settings. Previous studies have highlighted a range of transcription
factors, small molecules, and microRNA in controlling cell fates, which led to the development of new
neuronal reprogramming and differentiation methods with better efficiency and specificity. We expect
further understanding of the signals involved in development and cell fate determination would
advance the field of cellular reprogramming. Future studies to examine the therapeutic potential of
transplantation of in vitro cells, as well as in vivo reprogramming, will be an exciting research direction
to advance the development of novel neuroregenerative strategies.
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